Dr. Reddy's Laboratories Ltd. Share Price

Dr Reddy’s US arm gets $32,350 IRS penalty

The penalty relates to a fiscal year reference misclassification during tax payment, with no material financial or operational impact reported. Dr Reddy’s Laboratories, Inc., a step-down wholly owned subsidiary, received the final IRS transcript dated September 25, 2026, on October 2. The company said the issue was limited to the classification of the fiscal year reference when the tax payment was made. Based on its assessment, the penalty does not have a material impact on financials, operations or other activities. For context, the subsidiary’s penalty is small relative to the scale of Dr Reddy’s operations, so I would not treat this as a fundamental earnings risk by itself. The more relevant point for investors is the company’s regulatory exposure in the US. On September 11, Dr Reddy’s disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico and issued two observations. The company has said it will respond within the stipulated timeline. My view is that the IRS penalty is largely an administrative issue unless further tax-related actions emerge. I would focus more on the outcome of the USFDA observations because regulatory developments can have a greater bearing on manufacturing continuity, compliance costs and future approvals. The next trigger to watch is Dr Reddy’s response to the two USFDA observations and any subsequent regulatory update. Dr Reddy’s Laboratories Limited closed at ₹1,206.20 on October 1, 2026, down 2.17%. I would keep ₹1,206 as the immediate reference level and watch price action around this zone rather than treating the IRS penalty as a standalone fundamental concern.

Dr Reddy’s Gains Semaglutide Opportunity in Canada

Nifty Outlook for 28-Sep-2026 Looks Bearish

NIFTY 50 is expected to open with a cautious, slightly bearish bias on Wednesday, 30 September 2026, as geopolitical tensions, elevated crude oil prices ($106+), and ongoing FII outflows dominate the sentiment. The Daily MACD Histogram is below zero and the Hourly Histogram is also below zero indicating a bearish trend. The Daily RSI 14 below 30 and Hourly RSI 14 is also around 30 levels indicating a bearish trend. Thus, the overall trend of Nifty looks bearish, and the sellers are in control over the markets. Sell on rise would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a change in trend only if the price sustains above the resistance level. Can Initiate buying only if prices continue to sustain above the resistance level. I have provided Nifty Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Nifty Spot Resistance 1 - 22815 Resistance 2 - 22875 Support 1 - 22660 Support 2 - 22625 Happy Learning, Happy Trading and have a wonderful day. Top Gainers : ADANIENT, ADANIPORTS, DRREDDY. Top Losers : TITAN, WIPRO, HCLTECH.

Dr. Reddy’s: FY27 EBITDA Margin Target at 20%

Dr Reddy's Shines as Pharma Leads a Falling Market

Markets opened weak again today, with the Sensex sliding over 600 points and the Nifty testing 22,600, wiping out roughly ₹5 trillion in market cap, as oil prices continued climbing and raised fresh inflation worries. India VIX jumped over 8%, reflecting rising investor anxiety. But amid the broader carnage, one stock and one sector clearly stood apart. 1)

DR. REDDY’S LABORATORIES: RELATIVE STRENGTH IN A WEAK MARKET

Dr. Reddy’s Laboratories stood out on September 28 as one of the few Nifty 50 stocks trading strongly while the broader market faced heavy selling pressure. The Nifty 50 declined 1.56% to close at 22,780.25, while Dr. Reddy’s gained around 1.67% to ₹1,221. The contrast is important: when the benchmark falls sharply, stocks that manage to hold or gain can attract attention for relative-strength setups. The broader market was under pressure from elevated crude oil prices, higher US Treasury yields and continuing geopolitical uncertainty. India VIX also jumped more than 12% to 13.69, reflecting the rise in market volatility. For Dr. Reddy’s, the fundamental triggers are different from the broader macro picture. Investors can track the company's US generics business, new product launches, India formulations, margins and regulatory developments. Technical setup: ₹1,220–₹1,225 is the immediate zone to watch after Monday's close. A sustained move above this range with higher volumes could indicate that buyers are continuing to defend the stock despite broader market weakness. On the downside, ₹1,200 becomes an important psychological support. A move below this level could indicate that the recent relative strength is weakening. The broader Nifty setup also remains important. Technical analysts are watching 22,700 as a key support, while 22,800–22,900 is being viewed as an important recovery zone. • ₹1,220–₹1,225 breakout zone • ₹1,200 psychological support • US generics performance • Regulatory developments • Margin trajectory • Volume confirmation • Relative performance versus Nifty 50 View: Dr. Reddy’s ability to remain positive during a 1.56% Nifty decline makes it an interesting stock to monitor. The key confirmation will be whether this relative strength continues with price and volume support. Disclosure:I have no holding or financial interest in Dr. Reddy’s Laboratories at the time of writing.